Does GILTERITINIB Cause Malignant neoplasm progression? 22 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Malignant neoplasm progression have been filed in association with GILTERITINIB (Xospata). This represents 0.6% of all adverse event reports for GILTERITINIB.
22
Reports of Malignant neoplasm progression with GILTERITINIB
0.6%
of all GILTERITINIB reports
10
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From GILTERITINIB?
Of the 22 reports, 10 (45.5%) resulted in death, 3 (13.6%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GILTERITINIB. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does GILTERITINIB Cause?
Acute myeloid leukaemia (366)
Febrile neutropenia (346)
Off label use (334)
Platelet count decreased (327)
Pneumonia (302)
Myelosuppression (300)
Pyrexia (281)
Death (206)
Product use issue (189)
Hepatic function abnormal (181)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which GILTERITINIB Alternatives Have Lower Malignant neoplasm progression Risk?
GILTERITINIB vs GIMERACIL\OTERACIL\TEGAFUR
GILTERITINIB vs GINKGO
GILTERITINIB vs GIVINOSTAT
GILTERITINIB vs GIVOSIRAN
GILTERITINIB vs GLASDEGIB